K1932

N/A

Report date: 2026/03/19 17:03:45

Base Information

Drug NameK1932
Drug Alias NameK1932K-1932
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD19Anti-CD3
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Lvzhu Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Lvzhu Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A